WO2010146127A1 - Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability - Google Patents

Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability Download PDF

Info

Publication number
WO2010146127A1
WO2010146127A1 PCT/EP2010/058567 EP2010058567W WO2010146127A1 WO 2010146127 A1 WO2010146127 A1 WO 2010146127A1 EP 2010058567 W EP2010058567 W EP 2010058567W WO 2010146127 A1 WO2010146127 A1 WO 2010146127A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
branched
straight
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/058567
Other languages
English (en)
French (fr)
Inventor
Luigi A. Agrofoglio
Vincent Roy
Ugo Pradere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite d Orleans UFR de Sciences
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite d Orleans UFR de Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite d Orleans UFR de Sciences filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA2764827A priority Critical patent/CA2764827C/en
Priority to US13/377,652 priority patent/US8785629B2/en
Priority to JP2012515500A priority patent/JP2012530113A/ja
Priority to EP10725716.4A priority patent/EP2443130B1/en
Priority to ES10725716.4T priority patent/ES2601849T3/es
Publication of WO2010146127A1 publication Critical patent/WO2010146127A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015—Esters of acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Definitions

  • synthons useful for the synthesis of phosphonates compounds or derivatives showing better bioavailability processes for their preparation and their use in the synthesis of phosphonates compounds or derivatives showing better bioavailability.
  • ketophosphonates have been reported to have bone anabolic activity (see, e.g., WO 2004/026245) or to function as thyroid receptor ligands (see, e.g., US 2006/0046980), meanwhile bisphosphonic acids (also known as diphosphonic acids) and their salts are a class of compounds that are cytotoxic to osteoclasts and act to prevent bone resorption; when conjugated with alkylating moieties, bis-phosphonates have been reported to have antitumor activity (see, e.g., WO 9843987).
  • the pyrazolopyrimidine and pyrimidinyl bisphosphonic esters are anti-inflammatory agents (see, e.g., US 5397774), meanwhile macrocyclic phosphonates and amidophosphates have been reported to inhibit HCV (see, e.g., WO 2008096002); several phosphonate analogs of HIV protease inhibitors have an improved cellular accumulation properties (see, e.g., WO 2003090690); some heteroaromatic phosphonates were tested for a variety of biological activities including inhibition of fructose 1,6-bisphosphatase (FBPase) and activity toward AMP binding enzymes, such as adenosine kinase, and are useful in the treatment of diabetes and other diseases where inhibition of gluconeogenesis, control of blood glucose levels, reduction in glycogen storage, or reduction in insulin levels is beneficial (see, e.g., US 1998-135504P); dihydropyridine-5 -phosphonate derivatives are effective Ca antagonists (
  • nucleoside derivatives having antitumor activity such as 5- fluorouridine, 5-fluoro-2'-deoxyuridine or antiviral activity (in the treatment of AIDS, hepatitis B or C), such as 2',3'-dideoxynucleosides, acyclonucleoside phosphonates, exert their activity in phosphorylated form as phosphate or phosphonates analogs.
  • Compounds bearing a phosphonate group have a negatively charged ionic nature at physiological pH. The therapeutic activity of such compounds is consequently limited, on account of the low diffusion of negatively charged compounds across biological lipid membranes. In particular, charged compounds do not diffuse efficiently across cell membranes, or indeed across the cerebral barrier, which are lipidic in nature.
  • phosphonate drugs to phosphonate prodrugs.
  • the polar functional group is masked by a pro-moiety, which is labile under physiological conditions.
  • prodrugs are usually transported through hydrophobic biological barriers such as membranes and typically possess superior physicochemical properties in comparison to the parent drug.
  • nucleoside domain numerous studies showed the importance of having monophosphates or phosphonates of said nucleosides in order to present a better bioavailability (pro-nucleosides).
  • the present invention satisfies these and other needs by providing synthons useful for the synthesis of phosphonates derivatives showing better bioavailability, processes for their preparation and their use in the synthesis of phosphonates derivatives showing better bioavailability.
  • the inventors discovered new processes for synthesizing phosphonate synthons bearing a biolabile moiety which can be used to (a) either transform a said compound into its phosphonate analogue, (2) to synthesize a phosphonate compound.
  • R represents
  • Ri represents H, a straight or branched (Ci-Ce)alkyl group or a -(CH 2 ) m -R 2 group with R 2 selected from the group comprising Hydrogen, halogen, OH, N3, NH 2 , epoxy groups, leaving groups and carbonyl groups and m is an integer from 0 to 5,
  • H I ! represents a double or a triple bond
  • R R 2 with R 2 selected from the group comprising hydrogen, halogen, OH, N3, NH 2 , epoxy groups and analogs, leaving groups (sulfonates, halogens, ...), leaving groups involved into a transmetalation step catalyzed by Pd(O), and carbonyl groups, n is an integer from 0 to 5
  • X and Y independently of each other represent hydrogen, halogen, a straight or branched (Ci-Ce)alkyl group or an hydroxymethyl group, and R' and R" independently of each other
  • Ri and R'i are independently of each other hydrogen or (Ci-C 4 )alkyl group and
  • R' 2 is a straight or branched (Ci-Ce)alkyl group or straight or branched (Ci-Ce)alkoxy group
  • R'2 is methyl, then Rl and R' 1 are not simultaneously hydrogen, - a thioethylcarbonyl group of formula (3)
  • R 3 is a straight or branched (Ci-Ce)alkyl group
  • R' and R" form with the phosphate atom to which they are linked a cycloalkyle group of formula (4)
  • R 4 , R 5 , R 6 , et R 7 each independently represent a straight or branched (Ci-Ce)alkyl or aryl group or R 4 , and R 7 independently represent a straight or branched (Ci-Ce)alkyl or aryl group or R 5 and Re form together an aromatic ring, said aromatic ring being optionally substituted for example by a chloride atom with the proviso that
  • the compounds are those of formula
  • Ri is as defined before.
  • the compounds according to the invention may be prepared by any methods known from the one skilled in the art.
  • Another object of the invention is a process for making lipophilic pro-drugs comprising the step of contacting a drug D with a compound of formula (I) according to the invention.
  • said process is an olefm-metathesis reaction comprising the step of contacting at least one compound of formula (I), with a drug D which bears an olefin group as shown in the following scheme
  • said process is the step of contacting at least one compound according to anyone of claims 2, 4 and 5 with a drug D which bears a leaving group such as halogen, TfO, sulfones ...
  • said process is a process for making a compound of formula (II- 1)
  • D is a drug which bears an olefin group
  • A is a (Ci-Ce)alkenyl group comprising one or more double bonds, R' and R" independently of each other
  • Ri and R'i are independently of each other hydrogen or (Ci-C 4 )alkyl group and
  • R' 2 is a straight or branched (Ci-Ce)alkyl group or straight or branched (Ci-Ce)alkoxy group - a thioethylcarbonyl group of formula (3)
  • R 3 is a straight or branched (Ci-Ce)alkyl group - a lipohilic chain or
  • R' and R" forms with the phosphate atom to which they are linked a eye loalkyle group of formula (4)
  • R 4 , R 5 , R 6 , et R 7 each independently represent a straight or branched (Ci-Ce)alkyl or aryl group or R 4 , and R 7 independently represent a straight or branched (Ci-Ce)alkyl or aryl group or R 5 and R 6 form together an aromatic ring, said aromatic ring being optionally substituted for example by a chloride atom comprising the steps of: providing a compound of formula (5)
  • the process is a process for making a compound of formula (II-2)
  • Ri and R'i are independently of each other hydrogen or (Ci-C 4 )alkyl group and R' 2 is a straight or branched (Ci-Ce)alkyl group or straight or branched
  • R 3 is a straight or branched (Ci-Ce)alkyl group
  • R' and R" forms with the phosphate atom to which they are linked a cycloalkyle group of formula (4)
  • R 4 , R 5 , R 6 , et R 7 each independently represent a straight or branched (Ci-Ce)alkyl or aryl group or R 4 , and R 7 independently represent a straight or branched (Ci-Ce)alkyl or aryl group or R 5 and R 6 form together an aromatic ring, said aromatic ring being optionally substituted for example by a chloride atom comprising the steps of: d) providing a compound of formula (6) D-OH (6) e) reacting in a nucleophilic substitution reaction the compound of formula (6) with a compound of formula (1-2)
  • R', R", R 2 , n, X and Y are as defined in claim 3 to yield a compound of formula (II-2) and f) isolating the compound of formula (II-2).
  • D is a phosphonate derivative
  • the synthon according to the invention will be introduced by any reaction known from the one skilled in the art, for example by Diels and Alder reaction, Arbuzov reaction, olefin metathesis, nucleophilic substitution
  • the prodrugs may be prepared by a Mitsunobu reaction of an alcohol according to the following scheme.
  • halogen stands for fluorine, chlorine, bromine and iodine.
  • straight or branched (Ci-Ce)alkyl group stands for a straight-chain or branched hydrocarbon residue containing 1-6 C-atoms, such as, methyl, ethyl, propyl, ⁇ opropyl, n-butyl, isobutyl, t-butyl, n-hexyl.
  • (Ci-C6)alkoxy group stands for alkyl-O-with alkyl as defined above, e. g. methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, isobutoxy, t-butoxy and hexoxy.
  • straight or branched (C 2 -Ce)alkenyl groups stands for straight-chain or branched hydrocarbon residue containing one or more olefinic bonds and up to 6, preferably up to 4 C-atoms. Olefin and olefine may also be used to design an alkenyl group.
  • lipophilic chain or long-chain refers to the cyclic, branched or straight chain chemical groups that when covalently linked to a phosphonic acid to form a phosphonate ester increase oral bioavailability and enhance activity as for instance for some nucleoside phosphonates when compared with the parent nucleoside.
  • These lipophilic groups include, but are not limited to aryl, alkyl, alkoxyalkyl, and alkylglyceryl (such as hexadecyloxypropyl (HDP)-, octadecyloxyethyl-, oleyloxypropyl-, and oleyloxy ethyl- esters).
  • aromatic ring stands for, but is not limited to aryl, e.g. phenyl, benzyl, naphtyl or indanyl, said aryl group being optionally substituted.
  • leaving groups is an ion (metal) or substituent with the ability to detach itself from a molecule e.g. halogen, sulfonyl group for example /?-toluensulfonyloxy group and the like.
  • D is selected from a compound having a biological activity such as but not limited to neurotransmitters, stimulants, dopaminergic agents, tranquilizers, antidepressants, narcotic analgesics, narcotic antagonists, sedatives, hypnotics, anesthetics, antiepileptics/anticonvulsants, hormones such as the male and female sex hormones, peptides, anti-inflammatory steroids, non-steroidal anti-inflammatory agents/non-narcotic analgesics, memory enhancers, antibacterials/antibiotics, antineoplastics (anticancer/antitumor agents) and antiviral agents.
  • a biological activity such as but not limited to neurotransmitters, stimulants, dopaminergic agents, tranquilizers, antidepressants, narcotic analgesics, narcotic antagonists, sedatives, hypnotics, anesthetics, antiepileptics/anticonvulsants, hormones such as
  • POM states for pivaloyl oxymethyl and POC states for ⁇ opropyloxymethylcarbonate are directly usable to be biologically tested. Molecules bearing a HDP group should be first deprotected before being tested.
  • Another object of the invention is the use of compounds according to the invention as intermediates in the synthesis of phosphonates derivatives useful as pro-drugs.
  • Another object of the invention are compounds of formula
  • Still another object of the invention is a method of treating a disease comprising the administration to a patient in need thereof of a compound of formula
  • Another object of the invention is a method of making phosphonates derivatives useful as pro-drugs comprising a step involving the compounds according to the invention as intermediates.
  • Examples 1 to 15 illustrate the synthesis of the synthons according to the invention.
  • Examples 16 to 48 illustrate the synthesis of prodrugs from said synthons.
  • Compound 12 is synthesized according to the following scheme 12.
  • Rc H , F, Cl, Br, CH,
  • Example 18 N 1 ⁇ (E)- ⁇ bispivaloyloxymethylphosphinyl-l-butenyllS-fluorouracil and N 1 - KZ)- ⁇ bispivaloyloxymethylphosphinyl-l-butenyllS-fluorouracil
  • Example 20 N 1 - [(E)- 4-bispivaloyloxymethylphosphinyl-2-butenyll -5-chlor ouracil and N 1 - [(Z)- 4-bispivaloyloxymethylphosphinyl-2-butenyll -5-chlor ouracil
  • Example 21 N 1 - [(E)- 4-bispivaloyloxymethylphosphinyl-2-butenyll -5-bromour acil and N 1 - [(Z)- 4-bispivaloyloxymethylphosphinyl-2-butenyll -5-bromouracil
  • Rc H, F, Cl, Br, CH3
  • Example 23 N 1 - [(E)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll uracil and N 1 - [(Z)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll uracil
  • Example 24 N 1 - [(E)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll thymin and N 1 - [(Z)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll thymin
  • Example 25 N 1 - [(E)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll -5- fluorouracil and N 1 - [(Z)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll-5- fluorouracil
  • Example 26 N 1 - [(E)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll -5- chlorouracil and NM(Z)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll-5- chlorouracil
  • Example 27 N 1 - [(E)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll -5- bromorouracil and N 1 - [(Z)- 4-bisisopropyloxycarbonyloxymethylphosphinyl-2-butenyll- 5-bromorouracil
  • Example 28 General procedure for cross-metathesis with HDP-POC allylphosphonate
  • Example 32 N 1 - [(E)- O-hexadecyloxypropyl isopropyloxycarbonyloxymethyl- phosphinyl-2-butenyll thymin
  • Example 43 General procedure for conversion of 6-chloropurines to 6- cyclopropylamino purines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2010/058567 2009-06-18 2010-06-17 Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability Ceased WO2010146127A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2764827A CA2764827C (en) 2009-06-18 2010-06-17 Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
US13/377,652 US8785629B2 (en) 2009-06-18 2010-06-17 Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
JP2012515500A JP2012530113A (ja) 2009-06-18 2010-06-17 より良好な生物学的利用能を示すホスホネート誘導体の合成のためのホスホネートシントン
EP10725716.4A EP2443130B1 (en) 2009-06-18 2010-06-17 Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
ES10725716.4T ES2601849T3 (es) 2009-06-18 2010-06-17 Sintones de fosfonatos para la síntesis de derivados de fosfonatos que muestran mejor biodisponibilidad

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305562.2 2009-06-18
EP09305562A EP2270021A1 (en) 2009-06-18 2009-06-18 Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability

Publications (1)

Publication Number Publication Date
WO2010146127A1 true WO2010146127A1 (en) 2010-12-23

Family

ID=41171101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/058567 Ceased WO2010146127A1 (en) 2009-06-18 2010-06-17 Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability

Country Status (6)

Country Link
US (1) US8785629B2 (https=)
EP (2) EP2270021A1 (https=)
JP (1) JP2012530113A (https=)
CA (1) CA2764827C (https=)
ES (1) ES2601849T3 (https=)
WO (1) WO2010146127A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034719A1 (en) * 2010-09-14 2012-03-22 Centre National De La Recherche Scientifique Novel antiviral acyclic nucleoside phosphonates
WO2021177339A1 (ja) * 2020-03-04 2021-09-10 富士フイルム和光純薬株式会社 ホスホン酸エステルの製造方法、リン酸エステルの製造方法
JP2024526730A (ja) * 2021-07-15 2024-07-19 アルナイラム ファーマシューティカルズ， インコーポレイテッド ２，６－ジアミノプリン及び２－アミノアデニンのコンジュゲートをオリゴヌクレオチドに導入するための簡便な化学的アプローチ

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1805677A1 (de) 1967-10-30 1969-12-11 Merck & Co Inc Cis-Propenylverbindungen und Verfahren zu deren Herstellung
DE2002807A1 (de) 1969-01-23 1970-07-30 Merck & Co Inc Herstellung von Phosphonat-Antibiotika
JPS6069089A (ja) 1983-09-26 1985-04-19 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホネ−ト誘導体およびその製造法
US5397774A (en) 1991-07-03 1995-03-14 The Upjohn Company Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
DE4343599A1 (de) 1993-12-21 1995-06-22 Bayer Ag Verwendung von Phosphonsäureestern zur Behandlung von Hirnleistungsstörungen und Depressionen
WO1998043987A1 (en) 1997-03-27 1998-10-08 Novuspharma S.P.A. Bis-phosphonate confugates with alkylating moieties having antitumor activity
WO2003090690A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
WO2004026245A2 (en) 2002-09-19 2004-04-01 Ilex Oncology Research, Sarl Substituted phosphonate compounds having bone anabolic activity
US20060046980A1 (en) 2003-11-19 2006-03-02 Erion Mark D Novel phosphorus-containing thyromimetics
WO2008096002A1 (en) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE131825T1 (de) * 1990-06-13 1996-01-15 Arnold Glazier Phosphorylierte prodrugs
ZA941088B (en) * 1993-02-19 1995-09-27 Symphar Sa Substituted ketophosphonates the processes for their preparation and pharmaceutical compositions containing them
US5635449A (en) * 1995-04-07 1997-06-03 American Cyanamid Company Arylthioalkyl- and arylthioalkenylphosphonic acids and derivatives thereof useful as herbicidal agents
IT1281498B1 (it) * 1995-06-07 1998-02-18 Sardinian Antiviral Research C Pirazolo - derivati ad attivita' antitumorale, processo per la loro preparazione e composizioni farmaceutiche che li contengono , e
ES2218660T3 (es) * 1996-01-16 2004-11-16 Bristol-Myers Squibb Company Inhibidores aromaticos conformacionalmente restringidos de la proteina de transferencia de trigliceridos microsomales y procedimiento.
DE60038038T2 (de) * 1999-12-03 2009-02-12 The Regents of The University of California at San Diego, La Jolla Phosphonatverbindungen
US20040157804A1 (en) * 2002-10-16 2004-08-12 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
JP2010535701A (ja) * 2003-04-25 2010-11-25 ギリアード サイエンシーズ， インコーポレイテッド 抗癌ホスホネートアナログ
US20080261923A1 (en) * 2004-08-04 2008-10-23 Etzkorn Felicia A Alkene Mimics

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1805677A1 (de) 1967-10-30 1969-12-11 Merck & Co Inc Cis-Propenylverbindungen und Verfahren zu deren Herstellung
DE2002807A1 (de) 1969-01-23 1970-07-30 Merck & Co Inc Herstellung von Phosphonat-Antibiotika
JPS6069089A (ja) 1983-09-26 1985-04-19 Nissan Chem Ind Ltd ジヒドロピリジン−５−ホスホネ−ト誘導体およびその製造法
US5397774A (en) 1991-07-03 1995-03-14 The Upjohn Company Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
DE4343599A1 (de) 1993-12-21 1995-06-22 Bayer Ag Verwendung von Phosphonsäureestern zur Behandlung von Hirnleistungsstörungen und Depressionen
WO1998043987A1 (en) 1997-03-27 1998-10-08 Novuspharma S.P.A. Bis-phosphonate confugates with alkylating moieties having antitumor activity
WO2003090690A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
WO2004026245A2 (en) 2002-09-19 2004-04-01 Ilex Oncology Research, Sarl Substituted phosphonate compounds having bone anabolic activity
US20060046980A1 (en) 2003-11-19 2006-03-02 Erion Mark D Novel phosphorus-containing thyromimetics
WO2008096002A1 (en) 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GONG-XIN HE ET AL: "Chapter 3.6. Prodrugs of Phosphonates, Phosphinates, and Phosphates", PRODRUGS CHALLENGES AND REWARDS PART 1 (BOOK SERIES: BIOTECHNOLOGY: PHARMACEUTICAL ASPECTS), SPRINGER NEW YORK, US, vol. 5, 1 January 2007 (2007-01-01), pages 923 - 964, XP001539680, ISBN: 978-0-387-49782-2 *
SOMOGYI GABOR ET AL., TARGETED DRUG DELIVERY TO THE BRAIN VIA PHOSPHONATES DERIVATIVES, vol. 166, 2008, pages 15 - 26
SOMOGYI GABOR ET AL: "Targeted frug delivery to the brain via phosphonate derivatives", INTERNATIONAL JOURNAL OF PHARMACEUTICS 166(1988), 11 November 1998 (1998-11-11), pages 15 - 26, XP002555028 *

Also Published As

Publication number Publication date
EP2443130B1 (en) 2016-08-03
US8785629B2 (en) 2014-07-22
JP2012530113A (ja) 2012-11-29
EP2270021A1 (en) 2011-01-05
CA2764827A1 (en) 2010-12-23
EP2443130A1 (en) 2012-04-25
ES2601849T3 (es) 2017-02-16
CA2764827C (en) 2018-08-21
US20120142897A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
Starrett et al. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy) ethyl] adenine (PMEA)
AU2014268040B2 (en) Phosphoric acid/phosphonic acid derivatives and medicinal uses thereof
KR101178319B1 (ko) 포스폰산 유도체 및 ｐ2ｙ12 수용체 길항물질로서 이들의 용도
AU691527B2 (en) Nucleotide analogs
HUP0103641A2 (hu) Vírusellenes purinszármazékok és ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
CN106188192B (zh) 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途
US20010041690A1 (en) Process for making geminal bisphosphonates
CA2890676A1 (en) Phosphonucleosides useful in the treatment of viral disorders
Bessières et al. Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates
EP1866319A1 (en) Phosphono-pent-2-en-1-yl nucleosides and analogs
EP2443130B1 (en) Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
JPH05271260A (ja) グアニジノアルキル−１，１−ビスホスホン酸誘導体、それらの製造法およびそれらの使用
HU208701B (en) Process for producing new methylene bisphosphonic acid derivatives and medical preparatives containing them as active agent
Bubnov et al. Synthesis of functionalized organophosphorus analogs of α-and β-alanine
CN1827627B (zh) 新的无环核苷膦酸及其酯衍生物及其医药用途
Prishchenko et al. Synthesis of mono-and diphosphorus-substituted proline derivatives containing P–C–N fragments
KR20120124383A (ko) 신규한 뉴클레오시드 포스포네이트 및 유사체
Williams et al. Cyclic and acyclic phosphonate tyrosine ester prodrugs of acyclic nucleoside phosphonates
AU750407B2 (en) Prodrugs of phosphorous-containing pharmaceuticals
Williams Nucleoside Phosphonate Prodrugs: Synthesis and Antiviral Activity
US6441214B1 (en) Derivatives and analogs
Rosenberg et al. Preparation of isosters of 9-[2-(phosphonomethoxy) ethyl] adenine
CZ303164B6 (cs) Zpusob výroby substituovaných diamidu fosfonových kyselin
CA2624533A1 (en) Phosphoantigen salts of organic bases and methods for their crystallization
CZ20011145A3 (cs) Antivirové purinové deriváty a jejich použití

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10725716

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2010725716

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010725716

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2764827

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012515500

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13377652

Country of ref document: US